Survey in Post-Menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy - Full Text View

Survey in Post-Menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy (ARIES)

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00542594

Purpose

The purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.

Condition
Breast Cancer

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer Menopause

Drug Information available for: Anastrozole

Study Type:	Observational
Study Design:	Prospective
Official Title:	A Report Upon a Cohort of Post-Menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy for Hormone-Dependant Breast Cancer. Long-Term Tolerance Evaluation

Further study details as provided by AstraZeneca:

Estimated Enrollment:	2500
Study Start Date:	November 2004

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

woman treated with anastrozole as adjuvant therapy for hormone-dependant breast cancer in post-menopausal women with positive hormone-receptors

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00542594

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca France Medical Director

AstraZeneca

More Information

Study ID Numbers:	NIS-OFR-ARI-2005/1
Study First Received:	October 9, 2007
Last Updated:	October 10, 2007
ClinicalTrials.gov Identifier:	NCT00542594
Health Authority:	France: Conseil National de l'ordre des Médecins; France: CCTIRS; France: CNIL

Keywords provided by AstraZeneca:

breast cancer
anastrozole

Study placed in the following topic categories:

Anastrozole
Skin Diseases
Breast Neoplasms
Menopause
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal
Antineoplastic Agents

Therapeutic Uses
Enzyme Inhibitors
Aromatase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009